Thousands of people a year with advanced breast cancer will benefit from a life-extending drug that has been fast-tracked onto the frontline of NHS patient care.

The drug, alpelisib, will be used in combination with the hormone therapy, fulvestrant, to target the gene that causes fast-growing tumours.

Read more – NHSE & I (14/7/22)